These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 37211261

  • 1. In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial.
    Stewart AG, Bauer MJ, Butkiewicz D, Hinton A, Henderson A, Harris PNA, Paterson DL.
    Int J Antimicrob Agents; 2023 Aug; 62(2):106858. PubMed ID: 37211261
    [Abstract] [Full Text] [Related]

  • 2. Favourable effect of clavulanic acid on the minimum inhibitory concentrations of cefixime and ceftibuten in ESBL-producing Escherichia coli and Klebsiella pneumoniae.
    Martinez-Guerra BA, Xancal-Salvador LF, Esteban-Kenel V, Tello-Mercado AC, Bobadilla-Del-Valle M, Sifuentes-Osornio J, Ponce-de-Leon A, Gonzalez-Lara MF.
    J Glob Antimicrob Resist; 2024 Sep; 38():212-215. PubMed ID: 38945364
    [Abstract] [Full Text] [Related]

  • 3. In Vitro Activity of Cefotetan against ESBL-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Isolates from the MERINO Trial.
    Stewart AG, Cottrell K, Henderson A, Vemuri K, Bauer MJ, Paterson DL, Harris PNA.
    Microbiol Spectr; 2021 Sep 03; 9(1):e0022621. PubMed ID: 34232101
    [Abstract] [Full Text] [Related]

  • 4. Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing Escherichia coli.
    Al-Tamimi M, Abu-Raideh J, Albalawi H, Shalabi M, Saleh S.
    Microb Drug Resist; 2019 Oct 03; 25(8):1132-1141. PubMed ID: 31107146
    [Abstract] [Full Text] [Related]

  • 5. In Vitro and In Vivo Activity of Amoxicillin-Clavulanate Combined with Ceftibuten or Cefpodoxime Against Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae.
    Gupta A, Malik S, Kaminski M, Landman D, Quale JM.
    Microb Drug Resist; 2022 Apr 03; 28(4):419-424. PubMed ID: 35451880
    [Abstract] [Full Text] [Related]

  • 6. Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections.
    Birgy A, Madhi F, Jung C, Levy C, Cointe A, Bidet P, Hobson CA, Bechet S, Sobral E, Vuthien H, Ferroni A, Aberrane S, Cuzon G, Beraud L, Gajdos V, Launay E, Pinquier D, Haas H, Desmarest M, Dommergues MA, Cohen R, Bonacorsi S, Group of the National Observatory of Urinary tract Infection due to ESBL-producing Enterobacteriaceae in children.
    J Antimicrob Chemother; 2021 Oct 11; 76(11):2839-2846. PubMed ID: 34453533
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes.
    Mendes RE, Rhomberg PR, Watters AA, Castanheira M.
    J Antimicrob Chemother; 2022 Feb 23; 77(3):689-694. PubMed ID: 34849977
    [Abstract] [Full Text] [Related]

  • 8. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S, Gaind R, Ranjan R, Deb M.
    J Infect Dev Ctries; 2009 Nov 21; 4(1):24-9. PubMed ID: 20130375
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE.
    Tenover FC, Raney PM, Williams PP, Rasheed JK, Biddle JW, Oliver A, Fridkin SK, Jevitt L, McGowan JE, Project ICARE.
    J Clin Microbiol; 2003 Jul 21; 41(7):3142-6. PubMed ID: 12843054
    [Abstract] [Full Text] [Related]

  • 10. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
    Bauernfeind A, Jungwirth R.
    Infection; 1991 Jul 21; 19(5):353-62. PubMed ID: 1800377
    [Abstract] [Full Text] [Related]

  • 11. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.
    Livermore DM, Mushtaq S, Nguyen T, Warner M.
    Int J Antimicrob Agents; 2011 May 21; 37(5):405-9. PubMed ID: 21276715
    [Abstract] [Full Text] [Related]

  • 12. In vitro evaluation of a new cefixime-clavulanic acid combination for gram-negative bacteria.
    Rawat D, Hasan AS, Capoor MR, Sarma S, Nair D, Deb M, Pillai P, Aggarwal P.
    Southeast Asian J Trop Med Public Health; 2009 Jan 21; 40(1):131-9. PubMed ID: 19323045
    [Abstract] [Full Text] [Related]

  • 13. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.
    Livermore DM, Hope R, Mushtaq S, Warner M.
    Clin Microbiol Infect; 2008 Jan 21; 14 Suppl 1():189-93. PubMed ID: 18154546
    [Abstract] [Full Text] [Related]

  • 14. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018-2020 Global Surveillance Collection.
    Karlowsky JA, Wise MG, Hackel MA, Pevear DC, Moeck G, Sahm DF.
    Antimicrob Agents Chemother; 2022 Nov 15; 66(11):e0093422. PubMed ID: 36286518
    [Abstract] [Full Text] [Related]

  • 15. Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections.
    Stewart AG, Harris PNA, Henderson A, Schembri MA, Paterson DL.
    J Antimicrob Chemother; 2020 Sep 01; 75(9):2384-2393. PubMed ID: 32443141
    [Abstract] [Full Text] [Related]

  • 16. Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: effect of large inocula.
    Medeiros AA, Crellin J.
    Pediatr Infect Dis J; 1997 Mar 01; 16(3 Suppl):S49-55. PubMed ID: 9076836
    [Abstract] [Full Text] [Related]

  • 17. In Vitro Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program.
    Karlowsky JA, Hackel MA, Stone GG, Sahm DF.
    Antimicrob Agents Chemother; 2023 Jan 24; 67(1):e0134622. PubMed ID: 36602322
    [Abstract] [Full Text] [Related]

  • 18. Cefixime and cefixime-clavulanate for screening and confirmation of extended-spectrum beta-lactamases in Escherichia coli.
    Al-Tamimi M, Albalawi H, Shalabi M, Abu-Raideh J, Khasawneh AI, Alhaj F.
    Ann Clin Microbiol Antimicrob; 2022 May 22; 21(1):20. PubMed ID: 35599329
    [Abstract] [Full Text] [Related]

  • 19. Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?
    Moland ES, Sanders CC, Thomson KS.
    J Clin Microbiol; 1998 Sep 22; 36(9):2575-9. PubMed ID: 9705395
    [Abstract] [Full Text] [Related]

  • 20. Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases.
    Chatwin CL, Hamrick JC, Trout REL, Myers CL, Cusick SM, Weiss WJ, Pulse ME, Xerri L, Burns CJ, Moeck G, Daigle DM, John K, Uehara T, Pevear DC.
    Antimicrob Agents Chemother; 2021 Jul 16; 65(8):e0055221. PubMed ID: 34001510
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.